Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 23, 2022
Discovery & Translation

Enhancer elements for tissue regeneration; plus Alentis’ mAb for fibrosis and more

BioCentury’s roundup of translational news
BioCentury | Jun 25, 2021
Translation in Brief

Identifying KRAS G12C resistance mechanisms through genomic profiling; plus argenx, Revolution and Tenaya

BioCentury’s roundup of translational news
BioCentury | Oct 19, 2018
Company News

Revolution acquiring Warp Drive

BioCentury | Jun 12, 2018
Emerging Company Profile

A Cancer Target Revolution

How Revolution atypically inhibits SHP-2 and other difficult-to-drug targets for cancer
BioCentury | Apr 27, 2018
Financial News

Nextech leads Revolution Medicines' $56M series B

BioCentury | Apr 27, 2018
Finance

Revolution revamp

How Revolution’s SHP-2 inhibitor persuaded Nextech to back $56 million series B
BioCentury | Apr 24, 2018
Financial News

Nextech leads Revolution Medicines' $56M series B

Items per page:
1 - 10 of 19